Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Beyond Eosinophils: Proteomics to Identify Potential Biomarkers of Organ Damage and Response to MEPOLIZUMAB in EGPA

NCT07343661 is registered in ClinicalTrials.gov with Azienda Ospedaliero Universitaria di Cagliari as lead sponsor.

NCT NCT07343661
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07343661 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Beyond Eosinophils: Proteomics to Identify Potential Biomarkers of Organ Damage and Response to MEPOLIZUMAB in EGPA
Lead sponsor
Azienda Ospedaliero Universitaria di Cagliari
Phase
Phase 4
Overall status
Enrolling by invitation
Start date
October 17, 2025
Completion date
September 30, 2028
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

egpa - eosinophilic granulomatosis with polyangiitis, eosinophilic asthma, severe asthma